Advertisement

Second-Line Endocrine Treatment in Advanced Prostate Cancer

  • C. Mahler
Conference paper
  • 26 Downloads
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

Primary failure of first-line endocrine therapy is seen in about 20% of all prostatic cancers and is attributed to hormonal independence or to unresponsiveness of the tumour. Secondary failure occurs when an initially responsive cancer escapes the control of the first-line endocrine treatment (orchidectomy, oestrogens, LHRH analogues, antiandro-gens), the testosterone levels still being under castration values. This escape is considered to be due to the selection and/or cloning of pre-existing or de novo appearing hormone-resistant cell lines and occurs in the majority of patients within a period of 18 to 30 months after the start of treatment.

Keywords

Prostatic Cancer Medroxyprogesterone Acetate Cyproterone Acetate Adrenal Suppression LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nesbit RM and Baum WC: Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1,818 cases. JAMA 1950 (143):1317–1320CrossRefGoogle Scholar
  2. 2.
    Robinson RMG, Shearer RJ, Fergusson JD: Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 1974 (46):555PubMedCrossRefGoogle Scholar
  3. 3.
    Stoliar B, Albert DJ: SCH 13521 in the treatment of advanced carcinoma of the prostate. J Urol 1974 (111):803PubMedGoogle Scholar
  4. 4.
    Sogani PC, Ray B, Whitmore WF Jr: Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment. Urology 1975 (6):164PubMedCrossRefGoogle Scholar
  5. 5.
    Labrie F, Dupont A, Bélanger A, Giguère M, Borsanyi JP, Lacourcière Y, Emond J, Monfette G, Lachance R: The importance of combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in previously untreated as well as previously treated patients with advanced prostate cancer. In: JGM Klijn, R Paridaens, JA Foekens (eds) Hormonal Manipulation of Cancer: Peptides, Growth Factors and (Anti)-Steroidal Agents. Raven Press, New York 1986Google Scholar
  6. 6.
    Jordan WP, Blackard CE and Byar DP: Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 1977 (70):1411–1413PubMedGoogle Scholar
  7. 7.
    Biorn CL, Gray CP and Strauss E: Orchiectomy after presumed estrogen failure in treatment of carcinoma of the prostate. West J Med 1979 (130):363–364PubMedGoogle Scholar
  8. 8.
    Frenster JH, Hovsepian JA and the VACURG Group: Regained response to stilbestrol therapy after orchiectomy in advanced prostate carcinoma. Proc Amer Ass Cancer Res 1979 (20):296Google Scholar
  9. 9.
    Stone AR, Hargreave TB and Chisholm GD: The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer. Br J Urol 1980 (52):535–538PubMedCrossRefGoogle Scholar
  10. 10.
    Denis L and Nowé P: Bilateral orchiectomy in patients with progressive advanced prostatic cancer. Acta Urol Belg 1980 (48):113–116PubMedGoogle Scholar
  11. 11.
    Klugo RC, Farah RN and Cerny JC: Bilateral orchiectomy for carcinoma of prostate. Urology 1981 (17):49–50PubMedCrossRefGoogle Scholar
  12. 12.
    Klijn JGM, Nielander AJM, Alexieva-Figusch J, Van Putten WLJ: Orchidectomy and oestrogens as secondary forms of treatment for metastatic prostatic cancer. In: Schroeder FH, Richards B (eds) Therapeutic Principles in Metastatic Prostatic Cancer. Alan R Liss, New York 1985 pp 335–349Google Scholar
  13. 13.
    Fossa SO, Ogreid P, Karlsen S, Havelan H, Jensen J, Trovag A: High dose medroxyprogesterone acetate (MPA) versus prednisolone (P) in hormone-resistant prostatic cancer. In: Bracci U, Di Silverio F (eds) Advances in Urologicai Oncology and Endocrinology. Acta Medica, Rome1984 pp 433–437Google Scholar
  14. 14.
    Huggins C, Scott W: Bilateral surrenalectomy in prostatic cancer. Ann Surg 1945 (122):1031CrossRefGoogle Scholar
  15. 15.
    Baker WJ: Bilateral adrenalectomy for carcinoma of the prostate gland. Preliminary Report. J Urol 1953 (70/2):275Google Scholar
  16. 16.
    Scardino PL, Prince CL, McGoldrick TA: Bilateral adrenalectomy for prostatic cancer. J Urol 1953 (70/1):100Google Scholar
  17. 17.
    Whitmore WF, Randall HT, Pearson OH, West CD: Adrenalectomy in the treatment of prostatic cancer. Geriatrics 1954 (9):62PubMedGoogle Scholar
  18. 18.
    Fergusson JD: Total adrenalectomy for malignant disease of the prostate and breast. Proc Royal Soc Med 1954(47):1007Google Scholar
  19. 19.
    Morales PA, Brendler H, Hotchkiss RS: The role of the adrenal cortex in prostatic cancer. J Urol 195 (73/2):399Google Scholar
  20. 20.
    Mac Farlane DA, Thomas LP, Harrison JH: A survey of total adrenalectomy in cancer of the prostate. Am J Surg 1960 (99):562PubMedCrossRefGoogle Scholar
  21. 21.
    Schoonees R, Schalch DC, Reynoso G, Murphy GP: Bilateral adrenalectomy for advanced prostatic carcinoma. J Urol 1972 (108/1):123Google Scholar
  22. 22.
    Mahoney EM, Harrison JH: Bilateral adrenalectomy for palliative treatment of prostatic cancer. J Urol 1972(108):936PubMedGoogle Scholar
  23. 23.
    Bhanalaph T, Varkarakis M, Murphy G: Current status of bilateral adrenalectomy on advanced prostatic carcinoma. Ann Surg 1974 (179):17–23PubMedCrossRefGoogle Scholar
  24. 24.
    Miller G, Hinnan F: Cortisone treatment in advanced carcinoma of the prostate. J Urol (Balt imore)1954 (72):486–496Google Scholar
  25. 25.
    Fergusson JD: Limits and indications for adrenalectomy and hypophysectomy in the treatment of prostatic cancer. In: Bracci, Di Silverio (eds) Hormonal Therapy of Prostatic Cancer. Cofese Edizioni, Palermo 1975 pp 201–207Google Scholar
  26. 26.
    Sanford E, Drago J, Rohner T et al: Aminoglutethimide medical adrenalectomy for advanced prostatic cancer. J Urol (Baltimore) 1976 (115):170–174Google Scholar
  27. 27.
    Robinson MRG, Shearer RJ, Fergusson JD: Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 1974 (46):444–559CrossRefGoogle Scholar
  28. 28.
    Rostom AY, Folkes A, Lord C, Notley RG, Schweitzer FAW and White WF: Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol 1982 (54):552–555PubMedCrossRefGoogle Scholar
  29. 29.
    Lippman A et al: Aminoglutethimide for metastatic prostatic cancer. Proc ASCO 1983 (144) abstr C–563Google Scholar
  30. 30.
    Bauer HW, Schmeller NT, Schmiedt E: Adrenal suppression with aminoglutethimide in advanced prostatic carcinoma. J Urol 1984 (131):207A (abstr 413)Google Scholar
  31. 31.
    Block M, Trump D, Rose DP, Cummings KB, Hogan TF: Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy. Cancer Treat Rep 1984 (68):719–722.PubMedGoogle Scholar
  32. 32.
    Drago JR, Santen RJ, Lipton A, Worgul TJ, Harvey HA, Boucher A, Manni A, Rohner TJ: Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 1984 (53):1447–1450PubMedCrossRefGoogle Scholar
  33. 33.
    Murray R, Pitt P: Aminoglutethimide in the treatment of advanced prostatic cancer. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds) Prostate Cancer. Part A: Research, Endocrine Treatment and Histopathology. Alan R Liss, New York 1987 pp 275–282Google Scholar
  34. 34.
    Crawford ED, Ahmann FR, Davis MA, Levasseur YJ: Aminoglutethimide in metastatic adenocarcinoma of the prostate. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds): Prostate Cancer. Part A: Research, Endocrine Treatment and Histopathology. Alan R Liss, New York 1987 pp 283–289Google Scholar
  35. 35.
    Elomaa I, Taube T, Blomqvist C, Rissanen P, Rannikko S, Alfthan O: Amino-glutethimide for advanced prostatic cancer resistant to conventional hormonal therapy. Eur Urol 1988 (14):104–106PubMedGoogle Scholar
  36. 36.
    Perry LA, Plowman PN, Rowell NP, Chard T: Androgen suppression by hydrocortisone without aminoglutethimide in orchidectomised men with prostate cancer. In: Abstract Book International Symposium on Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti)steroidal Agents. Rotterdam, June 4–6 1986 p 110Google Scholar
  37. 37.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourcière Y, Bélanger A, Lachance R, Emond J, Monfette G: Combination therapy with flutamide and castration (orchidectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced cancer of the prostate and bladder.In: Smith PH, Pavone-Macaluso M (eds) Management of Advanced Cancer of the Prostate and Bladder. Alan R Liss, New York 1988 pp 41–62Google Scholar
  38. 38.
    Beardwell CG: Clinical use of trilostane. In: Furr BSA and Wakeling AE (eds) Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action. Baillière Tindall, London 1986Google Scholar
  39. 39.
    Van den Bossche H, Lauwers W, Willemsens G, Cools W: Ketoconazole, an inhibitor of the cytochrome P-450-dependent testosterone synthesis. In: Schroeder FH, Richards B (eds) EORTC Genito-Urinary Group, Monograph 2, Part A: Therapeutic Principles in Metastatic Prostatic Cancer. Alan R Liss, New York 1985 pp 187–196Google Scholar
  40. 40.
    Pont A, Williams PL, Azhar S, Reitz RE, Bochra CH, Smith ER, Stevens DA: Ketoconazole blocks testosterone synthesis.Arch Intern Med 1982 (142):2137–2140PubMedCrossRefGoogle Scholar
  41. 41.
    Mahler C, Denis L, De Coster R: The endocrine effect of ketoconazole high doses (KHD). In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds) Prostate Cancer. Part A: Research, Endocrine Treatment and Histopathology. Alan R Liss, New York 1987 pp 291–297Google Scholar
  42. 42.
    Trachtenberg J, Halpern N and Pont A: Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1987 (130 part 2):152Google Scholar
  43. 43.
    Trachtenberg J and Eichenberger T: Extra-hormonal effects of imidazoles on human prostatic cancer. J Urol 1987 (137 part 2):115A, abstract 45Google Scholar
  44. 44.
    Debruyne FMJ, Witjes J and Members of the Dutch South-East Cooperative Study Group: Ketoconazole high dose (HD) in the management of metastatic prostatic carcinoma. J Urol 1986 (135 part 2):203A, abstract 397Google Scholar
  45. 45.
    Williams G, Kerle DJ, Ware H, Dobie A, Dunlop H, Smith C, Allen J, Yeo T and Bloom SR: Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 1986(58):45PubMedCrossRefGoogle Scholar
  46. 46.
    Bredt A, Brughers A, Girey G, Schottinger J, Helman N and Weisz J: Ketoconazole therapy for metastatic prostate cancer resistant to prior hormonal treatment. Proc Amer Soc Clin Oncol 1986 (5):99, abstract 385Google Scholar
  47. 47.
    Van Cangh PJ and Opsomer RJ: High dose ketoconazole as secondary form of therapy in metastatic prostatic cancer. J Urol 1986 (135 part 2):338A, abstract 934Google Scholar
  48. 48.
    Pont A: Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol 1987 (137):902PubMedGoogle Scholar
  49. 49.
    Havlin K, Jordan VC, Cummings K, Messing E and Trump DL: Ketoconazole (KC) in advanced prostatic cancer (CaP) refractory to initial hormonal therapy: a clinical and endocrinologic study. Proc Amer Soc Clin Oncol 1987 (6):106 abstract 416Google Scholar
  50. 50.
    MacKintosh FR, Nickx CC, MacKintosh CL and Hall SW: High dose ketoconazole (K) therapy for metastatic prostatic cancer (MPC): a clinico-pharmacologic phase II study. Proc Amer Soc Clin 1987(6):101 abstract 397Google Scholar
  51. 51.
    Johnson DE, Babaian RJ, von Eschenbach AC, Wishnow Kl and Tenney D: Ketoconazole therapy for hormonally refractive metastatic prostate cancer. Urology 1988 (31):132PubMedCrossRefGoogle Scholar
  52. 52.
    Jubelirer S and Hogan T: High dose ketoconazole for the treatment of hormone refractory metastatic prostatic carcinoma : 16 cases and review of the literature. J Urol 1989 (142):89–91PubMedGoogle Scholar
  53. 53.
    Mahler C: Ketoconazole. In: Khoury S and Chatelain C (eds) Urologie: Cancer de la Prostate. FUS et RGP 1988 pp 365–368Google Scholar
  54. 54.
    Mahler C, Denis L and De Coster R: The effects of a new imidazole derivative in advanced prostatic cancer. A preliminary report. In: Murphy G and Khoury S (eds) Therapeutic Progress in Urological Cancers. Alan R Liss, New York 1989 pp 205–209Google Scholar
  55. 55.
    Labrie F, Dupont A, Bélanger A, Giguère M, Lacourcière Y, Emond J, Monfette G, Bergeron V: Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985 (23):833PubMedCrossRefGoogle Scholar
  56. 56.
    Bracci U, Di Silverio F: Terapia chirurgica ed ormonale del carcinoma prostatico. In: Bracci U, Di Silverio F (eds) Terapia dei tumori ormonodipendenti. Acta Medica, Rome 1979 pp 173–201Google Scholar
  57. 57.
    Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G: Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy: 5 Year follow-up. Eur Urol 1980 (6):145–148PubMedGoogle Scholar
  58. 58.
    Kaisary AV, Fellows GJ, Smith JC: Antiandrogen (flutamide) therapy in management of relapsing metastatic prostatic carcinoma. J Urol 1987 (137):256AGoogle Scholar
  59. 59.
    Di Silverio F, Tenaglia R, Bizzari M, Biggio A, Saragnano R: Experience with flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. J Drug Dev 1987(1 suppl 1):10–16Google Scholar
  60. 60.
    Habenicht UF, Schroeder H, El Etreby F, Neumann F: Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer. In: Smith PH, Pavone-Macaluso M (eds): Management of Advanced Cancer of the Prostate and Bladder. Alan R Liss, New York 1988 pp 63–75Google Scholar
  61. 61.
    Beurton D, Grall J, Davody Ph and Cukier J: Treatment of prostatic cancer with cyproterone acetate as monotherapy. In: Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds) Prostate Cancer. Part A. Research, Endocrine Treatment and Histopathology. Alan R Liss, New York 1987 pp 369–378Google Scholar
  62. 62.
    Denis L: A new non-steroidal anti-androgen. In: Murphy G and Khoury S (eds) Therapeutic Progress in Urological Cancers. Alan R Liss, New York 1989 pp 205–209Google Scholar
  63. 63.
    Tunn UW: Cyproterone acetate in the management of prostatic cancer.In: Murphy G and Khoury S (eds) Therapeutic Progress in Urological Cancers. Alan R Liss, New York 1989 pp 205–209Google Scholar
  64. 64.
    Pavone-Macaluso M, Pavone C, Serrata V, Cacciatore M, Cavallo N, Romano C, Daricello G: Side-effects of various modalities of hormonal treatment of prostatic carcinoma. J Endocrinol Invest 1987 (10 suppl 2) abstractGoogle Scholar
  65. 65.
    MacFarlane JR, Tolley DA: Flutamide therapy for advanced prostatic cancer: a phase II study. Br J Urol 1985 (57):172–174PubMedCrossRefGoogle Scholar
  66. 66.
    De Voogt HJ: Second-line endocrine management:anti androgens and anti-estrogens. In: Schroeder FH, Richards B (eds) Therapeutic Principles in Metastatic Prostate Cancer. Alan R Liss, New York 1985 pp 351–357Google Scholar
  67. 67.
    Manni A, Santen R, Boucher A, Lipton A, Harvey H, White D, Simmonds M, Gordon R, Rohner I, Drago J, Wettlaufer J, Glode L: Androgen priming and chemotherapy in advanced prostate cancer. J Endocrinol Invest 1987 (10 suppl 2):32Google Scholar
  68. 68.
    Schally AV, Redding TW: Somatostatin analogs as adjuncts to agonists of LHRH in the treatment of experimental prostate cancer. Proc Natl Acad Sci USA 1987 (84):7275–7279PubMedCrossRefGoogle Scholar
  69. 69.
    Bogden A: Effects of BIM 23014 on prostatic tumours in the rat. In: BIM 23014. Information for Clinical Investigators. Ipsen Intern 1988Google Scholar
  70. 70.
    Könyves I: Estramustine Phosphate (Estracyt ®) in the treatment of prostatic carcinoma. Int Urol Nephrol 1989 (4):393–397CrossRefGoogle Scholar
  71. 71.
    Winnan Ewing M, Larocca RV, Stein CA, Myers CE and Linehan WM: Effect of Suramin on proliferation of human prostate carcinoma. Proc Am Assoc Cancer Res 1989(30):310Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • C. Mahler
    • 1
  1. 1.Department of EndocrinologyAlgemeen Ziekenhuis MiddelheimAntwerpBelgium

Personalised recommendations